Resolvin D1 (RvD1) is produced physiologically from the sequential oxygenation of DHA by 15- and 5-lipoxygenases. The 17(R)-epimer of RvD1 can also be generated with aspirin-treatment. Both RvD1 and its 17(R) configuration reduce human polymorphonuclear leukocyte (PMNL) transendothelial migration, the earliest event in acute inflammation. RvD1 exhibits antihyperalgesic effects in a rat model of adjuvant-induced arthritis and prevents and inhibits the TRP channels, TRPA1, TRPV3, and TRPV4, producing anti-nociceptive effects. Resolvins also specifically interact with human phagocytes via the ALX and GPR32 receptors and have been shown to improve insulin sensitivity in leptin receptor-deficient (db/db) mice, possibly related to the reduction of pro-inflammatory macrophages found in adipose tissues. Cayman"s Resolvin D1 ELISA Kit is a competitive assay that can be used for quantification of RvD1. Due to the number and variation of potential sample types, this assay has been validated in Cayman"s ELISA Buffer (Cay-400060) diluted to 1X (0.1 M potassium phosphate containing 0.1% BSA, 0.1% sodium chloride, 1 mM EDTA, and 0.01% sodium azide) and DMEM containing phenol red and 10% FBS. This assay has a range from 3.3-2,000 pg/ml and a sensitivity (80% B/B0) of approximately 15 pg/ml.